Anti-PCIF1 / Phosphorylated CTD-interacting factor 1

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. PCIF1 antibody detects Phosphorylated CTD-interacting factor 1, an mRNA cap-specific methyltransferase that modifies the first transcribed nucleotide at the 5' cap structure of mRNA. The UniProt recommended name is mRNA cap-specific adenosine N6 methyltransferase (PCIF1), also known as CAPAM or phosphorylated CTD-interacting factor 1. This enzyme catalyzes the methylation of N6-adenosine in the cap-adjacent nucleotide, creating the m6Am modification, a key regulator of mRNA stability and translation efficiency.Functionally, PCIF1 antibody identifies a 726-amino-acid nuclear protein that directly interacts with the C-terminal domain (CTD) of RNA polymerase II when it is phosphorylated on Ser5 residues. This interaction positions PCIF1 near nascent transcripts to catalyze co-transcriptional methylation. The resulting m6Am mark enhances mRNA translation efficiency and protects transcripts from decapping and degradation. Through this function, PCIF1 plays a central role in post-transcriptional gene regulation and RNA processing.The PCIF1 gene is located on chromosome 20q13.13 and encodes a methyltransferase that contains a SAM-dependent catalytic domain typical of N6-adenosine methyltransferases. Its activity is tightly linked to transcriptional elongation and is coordinated with other cap modifications such as m7G capping and 2'-O-methylation. PCIF1 also associates with components of the mRNA export machinery, suggesting a coupling between RNA methylation and nuclear export.Loss or dysregulation of PCIF1 affects global mRNA methylation profiles, leading to alterations in gene expression, differentiation, and stress response. Studies indicate that depletion of PCIF1 reduces m6Am abundance and decreases translation of specific mRNAs, particularly those involved in growth control and stress adaptation. Conversely, overexpression enhances translation of transcripts with cap-proximal adenosines, promoting cell survival under adverse conditions.PCIF1 antibody is widely used in research to examine RNA modification pathways, cap-binding protein interactions, and transcriptional regulation. It is valuable for immunoblotting, immunofluorescence, and co-immunoprecipitation assays to identify PCIF1 localization and activity. In cancer studies, aberrant PCIF1 expression correlates with altered methylation landscapes and tumor progression. PCIF1 has also been linked to viral RNA modification, influencing immune detection of viral transcripts.Through its role in mRNA cap regulation, PCIF1 coordinates multiple levels of gene expression control from transcription initiation to translation. NSJ Bioreagents provides PCIF1 antibody reagents validated for applications in RNA biology, epigenetic regulation, and transcriptional research.